A61K 9/1275
Lipoproteins or protein-free species thereof
Official title: Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
A61K9/1275 (Lipoproteins or protein-free species thereof) appears on 136 US grants and 198 published applications in this corpus.
Search patents in A61K- Granted patents
- 136
- Published applications
- 198
- Assignees
- 132
- Inventors
- 410
- Latest grant
- 23 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 3 | 0 |
| 1993 | 0 | 0 |
| 1994 | 3 | 0 |
| 1995 | 1 | 0 |
| 1996 | 3 | 0 |
| 1997 | 4 | 0 |
| 1998 | 5 | 0 |
| 1999 | 7 | 0 |
| 2000 | 2 | 0 |
| 2001 | 5 | 1 |
| 2002 | 3 | 4 |
| 2003 | 5 | 4 |
| 2004 | 0 | 7 |
| 2005 | 1 | 5 |
| 2006 | 0 | 3 |
| 2007 | 2 | 8 |
| 2008 | 3 | 9 |
| 2009 | 3 | 2 |
| 2010 | 3 | 3 |
| 2011 | 2 | 6 |
| 2012 | 4 | 6 |
| 2013 | 2 | 8 |
| 2014 | 5 | 11 |
| 2015 | 3 | 9 |
| 2016 | 5 | 12 |
| 2017 | 8 | 11 |
| 2018 | 7 | 7 |
| 2019 | 6 | 15 |
| 2020 | 6 | 9 |
| 2021 | 5 | 12 |
| 2022 | 3 | 13 |
| 2023 | 4 | 13 |
| 2024 | 6 | 5 |
| 2025 | 11 | 6 |
| 2026 | 3 | 9 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Myelin nanovesicles and uses thereof23 Jun 2026US 12,661,319 B2Consiglio Nazionale Delle Ricerche
- Dry powder formulations for messenger RNA7 Apr 2026US 12,594,245 B2Translate Bio, Inc.
- Leveraging lipid-protein interactions to engineer spatial organization in cell-free systems31 Mar 2026US 12,589,073 B2Northwestern University
- High density lipoprotein mimetic nanoparticles using lipid conjugated core scaffolds23 Dec 2025US 12,502,354 B2Northwestern University
- Drug delivery methods and compositions16 Dec 2025US 12,496,275 B2Mayo Foundation for Medical Education and Research
- Leveraging lipid-protein interactions to engineer spatial organization in cell-free systems8 Oct 2026US 2026/0306405 A1
- Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis6 Aug 2026US 2026/0224505 A1Icahn School of Medicine at Mount Sinai
- Dry Powder Formulations for Messenger RNA9 Jul 2026US 2026/0191791 A1Translate Bio, Inc.
- Peptide-lipid conjugates and application thereof4 Jun 2026US 2026/0151340 A1Vacino Biotech Co., Ltd.
- Innate Targeting of Adoptive Cellular Therapies23 Apr 2026US 2026/0108454 A1Qu Biologics Inc.
Most cited
By later US patents
- Use of green porphyrins to treat neovasculature in the eye116US 5,798,349 AMassachuesetts Eye & Ear Infirmary · 1998
- Pharmaceutical formulations that have a biologically active hydrophilic phase and a chylomicra-containing hydrophobic phase97US 5,656,289 APatralan Limited · 1997
- Emulsion formulations for hydrophilic active agents96US 6,610,321 B2University of Pittsburgh · 2003
- Blood-stable, cholesterol-free liposomes84US 5,043,164 AThe University of Tennessee Research Corporation · 1991
- Use of green porphyrins to treat neovasculature in the eye75US 6,225,303 B1Massachusetts Eye and Ear Infirmary · 2001